Liver Disease Diagnostics Market Report 2026

Liver Disease Diagnostics Market Overview

• Liver Disease Diagnostics market size has reached to $38.95 billion in 2025 • Expected to grow to $55.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Impact Of Rising Alcohol Consumption On Market Growth • Market Trend: Advancements In Early Detection And Non-Invasive Tools • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Liver Disease Diagnostics Market?

Liver disease diagnostics refer to the medical procedures and tests used to identify and assess various liver conditions, including liver cirrhosis, hepatitis, fatty liver disease, and liver cancer. These diagnostic methods often involve blood tests to check liver enzyme levels, imaging techniques like ultrasound or CT scans, and sometimes biopsy procedures to obtain tissue samples. The main diagnostic techniques in liver disease diagnostics are laboratory tests, imaging, endoscopy, biopsy, and other diagnostic techniques. Laboratory tests involve analyzing blood and other samples to detect liver diseases. It is used for various diseases, including non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma, and other diseases, and caters to various end users, including hospitals, laboratories, and others.

What Is The Liver Disease Diagnostics Market Growth Forecast?

The liver disease diagnostics market size is expected to see strong growth in the next few years. It will grow to $55.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to rising burden of NAFLD and NASH, growing awareness of preventive liver care, increasing adoption of advanced imaging techniques, expansion of population health screening programs, higher healthcare spending on diagnostics. Major trends in the forecast period include growing demand for early liver disease detection, rising use of non-invasive diagnostic techniques, increasing screening for fatty liver and fibrosis, expansion of routine liver function testing, rising clinical focus on disease progression monitoring.

Global Liver Disease Diagnostics Market Segmentation

1) By Diagnosis Technique: Laboratory Tests, Imaging, Biopsy, Other Diagnosis Techniques 2) By Disease: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Fibrosis, Cirrhosis, Hepatocellular Carcinoma, Other Diseases 3) By End Users: Hospitals, Laboratories, Other End Users Subsegments: 1) By Laboratory Tests: Blood Tests (Liver Function Tests, Hepatitis Panel), Enzyme Tests (ALT, AST, ALP), Serological Tests 2) By Imaging: Ultrasound Imaging, CT Scans, MRI, Elastography (FibroScan) 3) By Biopsy: Liver Biopsy (Needle Biopsy), Fine Needle Aspiration Biopsy, Laparoscopic Biopsy 4) By Other Diagnosis Techniques: Biomarker Testing, Fibrosis Scoring Systems

What Is The Driver Of The Liver Disease Diagnostics Market?

The increase in alcohol consumption is expected to propel the growth of the liver disease diagnostics market going forward. Alcohol consumption is increasing due to factors such as changing social norms, greater affordability, widespread availability, and rising stress or mental health challenges. Liver disease diagnostics are crucial in monitoring the impact of alcohol consumption on liver health, helping to detect early signs of liver damage such as fatty liver, hepatitis, or cirrhosis. For instance, in December 2024, according to the Bureau of Labor Statistics, a US-based government agency, in 2023, U.S. households spent an average of $294 on alcoholic beverages consumed at home and $343 on those consumed outside the home. Therefore, the increase in alcohol consumption is driving the growth of the liver disease diagnostics industry.

Key Players In The Global Liver Disease Diagnostics Market

Major companies operating in the liver disease diagnostics market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Fujifilm Holdings Corporation, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, bioMérieux SA, Echosens SA, Hologic Inc., Canon Medical Systems Corporation, GE HealthCare Technologies Inc., Mindray Bio-Medical Electronics Co. Ltd., Samsung Medison Co. Ltd., Bruker Corporation, Sysmex Corporation, DiaSorin S.p.A., Perspectum Diagnostics Ltd., Owlstone Medical Ltd., HEPQuant LLC, Aiforia Technologies Plc

Global Liver Disease Diagnostics Market Trends and Insights

Major companies operating in the liver disease diagnostics market are focusing on developing innovative solutions, such as non-invasive tools for liver assessment, to develop more accurate and efficient diagnostic methods. A non-invasive tool for liver assessment refers to diagnostic methods that evaluate liver conditions using techniques like elastography or blood tests, avoiding the need for invasive procedures like biopsies. For instance, in September 2024, City Imaging & Clinical, an India-based diagnostic center, launched FibroScan, a non-invasive diagnostic tool for liver assessment, aimed at early detection of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). This advanced technology allows for rapid and accurate measurements of liver stiffness and fat content without the need for invasive procedures like biopsies. The procedure is quick, typically lasting 5 to 15 minutes, involving the placement of a probe on the skin over the liver. The probe emits sound waves, which measure liver tissue stiffness, helping assess fibrosis or scarring.

What Are Latest Mergers And Acquisitions In The Liver Disease Diagnostics Market?

In August 2024, Quest Diagnostics, a US-based medical laboratory company, acquired LifeLabs for $1 billion. The acquisition of LifeLabs is expected to help Quest Diagnostics significantly enhance its operational capabilities, financial performance, and competitive positioning within the North American healthcare market. LifeLabs is a Canada-based laboratory company that offers liver disease diagnostics, particularly focusing on non-alcoholic fatty liver disease (NAFLD).

Regional Outlook

North America was the largest region in the liver disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Liver Disease Diagnostics Market?

The liver disease diagnostics market consists of revenues earned by entities by providing services such as liver disease diagnostics, imaging studies, fibrosis assessment, viral hepatitis screening, and alcohol-related liver disease evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver disease diagnostics market also includes sales of blood test kits, imaging devices, and biopsy needles and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Liver Disease Diagnostics Market Report 2026?

The liver disease diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the liver disease diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.